Exosome
Extracellular exosomes are small extracellular vesicles released by cells into the extracellular space and found in many body fluids, including human plasma, urine, and nipple discharge.
Extracellular exosomes are small extracellular vesicles released by cells into the extracellular space and found in many body fluids, including human plasma, urine, and nipple discharge. They carry membrane proteins, lipids, and nucleic acids that reflect the molecular state of their parent cells, making them important mediators of intercellular communication and attractive candidates for biomarker discovery, drug delivery, and therapeutic engineering. In biomedical research, exosomes are often discussed together with broader extracellular vesicle populations, but the term specifically refers to a nanoscale vesicular subtype with a defined biogenesis pathway.
From a therapeutic and translational perspective, exosomes are being investigated both as natural delivery vehicles and as disease-associated analytes. Their membrane composition and cargo can be exploited for targeted delivery of drugs, nucleic acids, or genome-editing systems, while their endogenous origin may offer advantages over synthetic carriers. At the same time, their abundance and molecular signatures are being studied for noninvasive sensing strategies in Cancer and other diseases, including breast cancer, bladder Cancer, and neurological and inflammatory disorders.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
26 papers study exosome directly. Those 26 are one subject: Extracellular Vesicle Medicine. Exosome research is moving from disease mechanisms toward engineered delivery, imaging-guided repair, antimicrobial therapy, and early clinical testing. Applications include liquid biopsy, neuroinflammation, ferroptosis, cancer immunometabolism, and ischemic tissue repair. No way of splitting those 26 scores better than chance. 1 paradigm shift and 1 new direction follow.
Exosomes can be disease-amplifying effectors rather than merely therapeutic carriers
The hepatocellular carcinoma study and the hypertrophic-scarring study both challenge the set’s predominantly reparative framing of exosomes. In hepatocellular carcinoma, tumor-derived EVs carrying MSTRG171708 reprogram regulatory T cells toward glycolysis, enhance immunosuppression, and promote lung metastasis; in hypertrophic scarring, TGF-β1-stimulated keratinocyte exosomes transfer LINC01605 to fibroblasts and amplify profibrotic TGF-β1/Smad signaling. Together, these independent disease models show that exosomes can actively drive pathology, so therapeutic use cannot assume that exosomal signaling is intrinsically beneficial or that the vesicles are merely passive delivery vehicles 42726156Sep 42320250Jun.
Exosomes can function as infectious vehicles for productive viral transmission
The Tembusu virus study gives exosomes a role absent from the other papers: TMUV-infected cells release exosomes containing viral genomic RNA and viral proteins, which enter recipient cells, suppress antiviral immune genes, and support productive infection through an NS4A–Rab27a-dependent mechanism. This extends exosomes beyond therapeutic delivery, biomarker detection, or host-cell signaling to direct transmission of an infectious agent 42572027Aug.
Recent Findings on exosome
Therapeutic Extracellular Vesicles: Engineered and source-derived exosomes and EVs deliver siRNA, microRNA, proteins, and small molecules to suppress ferroptosis, inflammation, fibrosis, or tumor progression in disease models 42687852Sep42663757Aug42102612May42162765May42302977Jun. Mechanistic studies attribute these effects to pathways including GPX4/ACSL4, AMPK/SIRT1/NFκB, USP21-BRD2, and miR-124/Calpain-1 signaling 42687852Sep42162765May42302977Jun42102612May. Scaffolds, imaging probes, and oral milk-derived EVs improve tissue localization, biological-barrier penetration, or controlled delivery while supporting neurorepair, revascularization, bone integration, and cardiac recovery 42638487Aug42726851Sep42690904Sep42275920Jun. Effects remain cargo- and source-dependent: tumor-derived and keratinocyte-derived EVs can promote immunosuppression, viral transmission, or fibrosis, whereas adipocyte-derived exosomes produce different responses across recipient cell types 42726156Sep42572027Aug42320250Jun42678968Sep. Translation is moving toward a phase I/II stroke trial and liquid-biopsy platforms, although several studies remain preliminary, including a protocol, animal models, in vitro systems, and diagnostic assays requiring further clinical validation 42749369Sep42725427Sep42611334Aug42520835Jul42215863May.
Written from 26 PubMed abstracts, each one cited by PMID above. Published: 2026-06-18. Last written: 2026-09-18 by GPT. Drafted by language models from published abstracts; not medical advice.